Genomics

Dataset Information

0

Loss of GM-CSF-dependent instruction of alveolar macrophages in COVID-19 provides a rationale for inhaled GM-CSF treatment (RNA-Seq)


ABSTRACT: Systemic GM-CSF promotes myelopoiesis and inflammation and GM-CSF blockade is being evaluated as treatment for COVID-19-associated hyperinflammation. Alveolar GM-CSF is however required for monocytes to differentiate into alveolar macrophages (AM) that control alveolar homeostasis and dampen inflammation. By mapping cross-species AM development stages to clinical lung samples, we discovered that COVID-19 is marked by defective GM-CSF-dependent AM instruction and accumulation of proinflammatory macrophages. In a multi-center, open-label, randomized, controlled trial in 81 non-ventilated COVID-19 patients with respiratory failure, we found that inhalation of rhu-GM-CSF did not improve mean oxygenation parameters compared with standard treatment. However, more patients on GM-CSF had a clinical response, and GM-CSF inhalation induced higher numbers of virus-specific CD8 effector lymphocytes and class-switched B cells, without exacerbating systemic hyperinflammation. This translational proof-of-concept study provides rationale for further testing of inhaled GM-CSF as non-invasive treatment to improve alveolar gas exchange and simultaneously boost anti-viral immunity in COVID-19

ORGANISM(S): Homo sapiens

PROVIDER: GSE216704 | GEO | 2022/11/03

REPOSITORIES: GEO

Similar Datasets

2022-11-03 | GSE216701 | GEO
2021-02-20 | GSE167118 | GEO
2017-10-09 | GSE104719 | GEO
2014-10-01 | GSE60528 | GEO
2014-10-01 | E-GEOD-60528 | biostudies-arrayexpress
2017-10-09 | GSE104718 | GEO
2014-11-27 | GSE63662 | GEO
2020-02-19 | PXD012794 | Pride
2012-05-20 | E-GEOD-37029 | biostudies-arrayexpress
2023-03-29 | PXD041180 | iProX